当前位置: 首页 > 期刊 > 《中外医学研究》 > 201435
编号:13655585
甲状腺乳头状癌术后有无残余甲状腺组织对131I清甲疗效的影响(3)
http://www.100md.com 2014年12月15日 《中外医学研究》 201435
     [8] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper D S,Doherty G M,et al.Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214.

    [9] Schlumber M J.Papillary and follicular thyroid carcinoma[J].N Engl J Med,1998,338(5):297-306.

    [10]张桂枝,谭健,刘雪辉,等.131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J].中华核医学杂志,2010,30(4):259-263.

    [11] Randolph G W,Daniels G H.Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid[J].Thyroid,2002,12(11):989-996.

    [12]朱瑞森,余永利,陆汉魁,等.大剂量131I治疗312例分化型甲状腺癌转移灶[J].中华核医学杂志,2002,22(6):325-327.

    [13]蒋宁一.肿瘤核医学[M].北京:人民卫生出版社,2002:288-293.

    [14] Edmonds C J,Hayes S,Kermode J C,et al.Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine[J].Br J Radiol,1977,50(599):799-807.

    (收稿日期:2014-08-07) (编辑:欧丽), 百拇医药(石飞 贾冰 高芸)
上一页1 2 3